Bio-cat, Inc.

Bio-cat Microbials LLC

Moore, Kenneth Gregory

Christopher Schuler

Christopher S Penet

Jessica Spears

Sebhat Gebrechristos

Edward Schuler

Deborah S Winetzky

Kelly Gregory

Robert Daniel Little, Jr

Caroline Helen Best

Gregory S Moore

K Gregory Moore

Laura Brutscher

James Farmar

Steve C Lamb

Sean Garvey

Kenneth Gregory Moore

Robert Daniel Little

A spore-formingspecies, and more particularly, astrain identified as BV379 is provided. Compositions comprising BV379 and methods of using the same are also provided.

Bacillus velezensis compositions and methods of use thereof

A spore-formingspecies, and more particularly, astrain identified as MB40 is provided. Compositions comprising the MB40 strain, methods of making products comprising the same, and methods of using the same are also provided.

Bacillus compositions and uses thereof

This invention provides compositions ofstrains and methods for using such compositions to inhibit the activity and/or growth of fungal pathogens of plants. In one embodiment, this invention provides a composition comprisingbacteria selected from the group consisting ofstrain CM-3,strain CM-33,BCM-CM5,ATCC-11946,BCM-01,NRRL-1875,10 DSM-10,NRRL-1650,BCM-07,DSM-36,DSM-11030, and combinations thereof. In another embodiment, this invention provides a method for preparing a bacterial composition comprising one or morestrains by growingstrain bacteria until the bacteria form spores, collecting said spores, and formulating said composition.

[object Object]

The invention relates to methods and compositions for reducing serum levels of triacylglycerides in human subjects. In particular, the invention relates to the oral administration of an effective amount of a fungal lipase formulation, to a human subject having borderline-high or high serum levels of triacylglycerides, for a time period sufficient to reduce serum triacylglyceride levels.

Methods and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase

Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from, alone or in combination with amylase or amyloglucosidase, protease and/or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

Composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency

Growing community of inventors

Charlottesville, VA, United States of America

Christopher Schuler